CNS Cluster Addiction Drug Development Pipeline Review 2017

Focus on Drug Addiction, Alcohol Addiction, Nicotine Addiction & Opioid Addiction - Research and Markets - Seite 2

There is a substantial degree of overlap between these indications in terms of the types of molecular target which are being studied. The mu and kappa-opioid receptors are the dominant molecular target across alcohol, drug and opioid addiction, and other neurotransmitter receptors such as the cannabinoid and dopamine receptors are common molecular targets across the three. In contrast, while such neurotransmitter receptors are present in the nicotine addiction pipeline, the opioid receptors are not, and the dominant molecular target is the orexin receptor type 1.

Scope

- Which companies are the most active within the pipeline for addiction therapeutics?

- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

- What are the most important R&D milestones and data publications to have happened in the field of addiction therapeutics?

Key Topics Covered:

1. Report Guidance

2. Executive Summary

3. Introduction

4. CNS Cluster Addiction Report Coverage

5. Therapeutics Development

6. Therapeutics Assessment

7. Companies Involved in Therapeutics Development

8. Dormant Projects

9. Discontinued Products

10. Product Development Milestones

11. Appendix

Companies Featured

• Companies Mentioned
• AbbVie Inc
• Alkermes Plc
• Aoxing Pharmaceutical Company Inc
• Aphios Corp
• Aquilus Pharmaceuticals Inc
• Astraea Therapeutics LLC
• BioCorRx Inc
• BioDelivery Sciences International Inc
• Bionex Pharmaceuticals LLC
• Bioprojet SCR
• Euthymics Bioscience Inc
• F. Hoffmann-La Roche Ltd
• Foresee Pharmaceuticals LLC
• H. Lundbeck A/S
• Immunovaccine Inc
• Indivior Plc
• InterveXion Therapeutics LLC
• Intra-Cellular Therapies Inc
• Kinnov Therapeutics SAS
• Kyorin Pharmaceutical Co Ltd
• Kyowa Hakko Kirin Co Ltd
• Lohocla Research Corp
• MedRev Pharma
• Orexo AB
• P2D Bioscience
• Pfizer Inc
• Relmada Therapeutics Inc
• SK Biopharmaceuticals Co Ltd
• Saniona AB
• Savant HWP Inc
• Stada Arzneimittel AG
• Teva Pharmaceutical Industries Ltd
• Titan Pharmaceuticals Inc
• Tonix Pharmaceuticals Holding Corp
• Zynerba Pharmaceuticals Inc

For more information about this report visit http://www.researchandmarkets.com/research/gt8blt/cns_cluster